推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Tyrosine phosphorylation controls brassinosteroid receptor activation by triggering membrane release of its kinase inhibitor

Y Jaillais, M Hothorn, Y Belkhadir… - Genes & …, 2011 - genesdev.cshlp.org
Receptor tyrosine kinases control many critical processes in metazoans, but these enzymes
appear to be absent in plants. Recently, two Arabidopsis receptor kinases—BRASSINOSTEROID
INSENSITIVE 1 (BRI1) and BRI1-ASSOCIATED KINASE1 (BAK1), the receptor and ...
Cited by 7 - Related articles - All 5 versions

Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells

M Sela, Y Bogin, D Beach, T Oellerich… - The EMBO …, 2011 - nature.com
Cooperatively assembled signalling complexes, nucleated by adaptor proteins, integrate information
from surface receptors to determine cellular outcomes. In T and mast cells, antigen receptor signalling
is nucleated by three adaptors: SLP-76, Gads and LAT. Three well-characterized SLP-76 ...
All 3 versions

The skeletal effects of the tyrosine kinase inhibitor nilotinib

S O'Sullivan, JM Lin, M Watson, K Callon… - Bone, 2011 - Elsevier
Nilotinib is a tyrosine kinase inhibitor (TKI) developed to manage imatinib-resistance in patients
with chronic myeloid leukaemia (CML). It inhibits similar molecular targets to imatinib, but is a
significantly more potent inhibitor of Bcr-Abl. Nilotinib exhibits off-target effects in other ...
Cited by 1 - All 3 versions

Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3

OA Guryanova, Q Wu, L Cheng, JD Lathia… - Cancer Cell, 2011 - Elsevier
Glioblastomas display cellular hierarchies containing tumor-propagating glioblastoma stem cells
(GSCs). STAT3 is a critical signaling node in GSC maintenance but molecular mechanisms underlying
STAT3 activation in GSCs are poorly defined. Here we demonstrate that the bone marrow ...
Cited by 2 - All 2 versions

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib

JE Chaft, GR Oxnard, CS Sima, VA Miller… - Clinical Cancer …, 2011 - AACR
... resistance to erlotinib or gefitinib -mutant lung cancer and acquired EGFR patients
with Disease flare after tyrosine kinase inhibitor discontinuation in ... Page 2. Disease
flare after tyrosine kinase inhibitor discontinuation in patients with ...

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451